Relevant literature on Health Technology Assessment

This resource provides a comprehensive bibliography on Health Technology Assessment (HTA). Users can locate relevant literature for specific regions or countries by using the table of contents on the side.

General

  1. Abbas, N., S. S. Hasan, and Z. U. D. Babar. ‘Access to Medicines in the United Kingdom: A Review of HTA Decisions for New Medicines’. Value in Health 23 (1 December 2020): S665. https://doi.org/10.1016/j.jval.2020.08.1589
  2. Abbing, Henriette D.C. Roscam. ‘EU Cross-Border Healthcare and Health Law Editorial’. European Journal of Health Law 22, no. 1 (2015): 1-12. https://doi.org/10.1163/15718093-12341348.
  3. Abecassis, Philippe, and Nathalie Coutinet. ‘Politique d’austérité et politique du médicament en France et au Royaume-Uni : une analyse de leurs répercussions sur le modèle de production pharmaceutique’. La Revue de l’Ires 91-92, no. 1-2 (2017): 111-140. https://doi.org/10.3917/rdli.091.0111.
  4. Abelson, Julia. ‘Patient Engagement in Health Technology Assessment: What Constitutes “Meaningful” and How We Might Get There’. Journal of Health Services Research & Policy 23, no. 2 (2018): 69-71. http://dx.doi.org/10.1177/1355819618756936.
  5. Aissaoui, Djamel, and Javier Barcenilla. ‘Aide à l’évaluation et à la prescription lors de la conception de gérontechnologies’. Gérontologie et société 43 /  164, no. 1 (2021): 203-21. https://doi.org/10.3917/gs1.164.0203.
  6. Akhmetov, Ildar, and Rostyslav V. Bubnov. ‘Assessing Value of Innovative Molecular Diagnostic Tests in the Concept of Predictive, Preventive, and Personalized Medicine’. EPMA Journal 6, no. 1 (30 September 2015): 19. https://doi.org/10.1186/s13167-015-0041-3.
  7. Altavilla, Annagrazia. ‘Introduction: Special Issue on Innovative Medicine and Research: Ethical, Legal and Regulatory Issues’. European Journal of Health Law 27, no. 3 (15 June 2020): 187-193. https://doi.org/10.1163/15718093-BJA10019.
  8. Anderson, Michael, Michael Drummond, David Taylor, Alistair McGuire, Paul Carter, and Elias Mossialos. ‘Promoting Innovation While Controlling Cost: The UK’s Approach to Health Technology Assessment’. Health Policy 126, no. 3 (1 March 2022): 224-233. https://doi.org/10.1016/j.healthpol.2022.01.013.
  9. Angelis, Aris, Ansgar Lange, and Panos Kanavos. ‘Using Health Technology Assessment to Assess the Value of New Medicines: Results of a Systematic Review and Expert Consultation across Eight European Countries’. European Journal of Health Economics 19, no. 1 (January 2018): 123-152. https://doi.org/10.1007/s10198-017-0871-0.
  10. Annemans, Lieven, Irina Cleemput, Steven Simoens, Francis Arickx, Frank Hulstaert, and Marc Bogaert. ‘The Increasing Role of Health Economic Evaluations in Drug Development’. Drug Development Research 71, no. 8 (2010): 457-462. https://doi.org/10.1002/ddr.20420.
  11. Armoiry, Xavier, Hans-Martin Spath, Aileen Clarke, Martin Connock, Paul Sutcliffe, and Claude Dussart. ‘Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma’. Journal of Market Access & Health Policy 7, no. 1 (2019): 1648971. https://doi.org/10.1080/20016689.2019.1648971.
  12. Ascef, Bruna de Oliveira, Ana Carolina de Freitas Lopes, and Patrícia Coelho de Soárez. ‘Health Technology Assessment of Biosimilars Worldwide: A Scoping Review’. Health Research Policy and Systems 18, no. 1 (26 August 2020): 95. https://doi.org/10.1186/s12961-020-00611-y.
  13. Azzopardi-Muscat, Natasha, Peter Schroder-Back, and Helmut Brand. ‘The European Union Joint Procurement Agreement for Cross-Border Health Threats: What Is the Potential for This New Mechanism of Health System Collaboration’. Health Economics Policy and Law 12, no. 1 (2017): 43-60.
  14. Barna, Alexandre, Teresita M. Cruz-Sanchez, Karen Berg Brigham, Cong-Tri Thuong, Finn Boerlum Kristensen, and Isabelle Durand-Zaleski. ‘Evidence Required by HTA and Reimbursement Bodies Evaluating Diagnostic or Prognostic Algorithms That Include Omics Data’. International Journal of Technology Assessment in Health Care 34, no. 4 (January 2018): 368-377. https://doi.org/10.1017/S026646231800048X.
  15. Bartos, Blanka. ‘What Are the Changes in 2023 for Access to Advanced Therapy Medicinal Products (ATMPs) in France?’ European Journal of Health Law 31, no. 2 (29 January 2024): 187-208. https://doi.org/10.1163/15718093-bja10121.
  16. Beletsi, Alexandra, Vassiliki Koutrafouri, Eleftheria Karampli, and Elpida Pavi. ‘Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union’. Value in Health Regional Issues 16 (1 September 2018): 81-91. https://doi.org/10.1016/j.vhri.2018.08.002.
  17. Bélisle-Pipon, Jean-Christophe, Vincent Couture, Marie-Christine Roy, Isabelle Ganache, Mireille Goetghebeur, and I. Glenn Cohen. ‘What Makes Artificial Intelligence Exceptional in Health Technology Assessment?’ Frontiers in Artificial Intelligence 4 (2021): 736697. https://doi.org/10.3389/frai.2021.736697.
  18. Bellemare, Christian A., Pierre Dagenais, Suzanne K.-Bédard, Jean-Pierre Béland, Louise Bernier, Charles-Étienne Daniel, Hubert Gagnon, Georges-Auguste Legault, Monelle Parent, and Johane Patenaude. ‘Ethics in Health Technology Assessment: A Systematic Review’. International Journal of Technology Assessment in Health Care 34, no. 5 (January 2018): 447-457. https://doi.org/10.1017/S0266462318000508.
  19. Bernier, Louise, Georges-Auguste Legault, Charles-Etienne Daniel, Suzanne K. Bedard, Jean-Pierre Beland, Christian A. Bellemare, Pierre Dagenais, Hubert Gagnon, Monelle Parent, and Johane Patenaude. ‘Legal Governance in HTA: Environment, Health and Safety Issues/Ethical, Legal and Social Issues (EHS/ELSI), the Ongoing Debate’. Canadian Journal of Bioethics / Revue Canadienne de Bioethique 3, no. 1 (2020): 83-92.
  20. Bijlmakers, Leon, Debjani Mueller, Rabia Kahveci, Yingyao Chen, and Gert Jan van der Wilt. ‘Integrate-HTA: A Low-and-Middle-Income Country Perspective’. International Journal of Technology Assessment in Health Care 33, no. 5 (January 2017): 599-604. https://doi.org/10.1017/S0266462317000927.
  21. Blüher, Maximilian, Sita J. Saunders, Virginie Mittard, Rafael Torrejon Torres, Jason A. Davis, and Rhodri Saunders. ‘Critical Review of European Health-Economic Guidelines for the Health Technology Assessment of Medical Devices’. Frontiers in Medicine 6 (29 November 2019). https://doi.org/10.3389/fmed.2019.00278.
  22. Borras, Josep M., Julieta Corral, Ajay Aggarwal, Riccardo Audisio, Josep Alfons Espinas, Josep Figueras, Peter Naredi, et al. ‘Innovation, Value and Reimbursement in Radiation and Complex Surgical Oncology: Time to Rethink’. Radiotherapy and Oncology 169 (1 April 2022): 114-123. https://doi.org/10.1016/j.radonc.2021.08.002.
  23. Boudard, Aurélie, Nicolas Martelli, Patrice Prognon, and Judith Pineau. ‘Clinical Studies of Innovative Medical Devices: What Level of Evidence for Hospital-Based Health Technology Assessment?’ Journal of Evaluation in Clinical Practice 19, no. 4 (2013): 697-702. https://doi.org/10.1111/jep.12024.
  24. Brenna, Elenka, Barbara Polistena, and Federico Spandonaro. ‘The Implementation of Health Technology Assessment Principles in Public Decisions Concerning Orphan Drugs’. European Journal of Clinical Pharmacology 76, no. 6 (1 June 2020): 755-764. https://doi.org/10.1007/s00228-020-02855-7.
  25. Calabrò, G. E., G. La Torre, C. de Waure, P. Villari, A. Federici, W. Ricciardi, and M. L. Specchia. ‘Disinvestment in Healthcare: An Overview of HTA Agencies and Organizations Activities at European Level’. BMC Health Services Research 18, no. 1 (1 March 2018): 148. https://doi.org/10.1186/s12913-018-2941-0.
  26. Cangelosi, Michael, Akriti Chahar, and Simon Eggington. ‘Evolving Use of Health Technology Assessment in Medical Device Procurement—Global Systematic Review: An ISPOR Special Interest Group Report’. Value in Health 26, no. 11 (1 November 2023): 1581-1589. https://doi.org/10.1016/j.jval.2023.06.005.
  27. Cheung, K.L., S.M.A.A. Evers, H. De Vries, P. Levy, S. Pokhrel, T. Jones, M. Danner, et al. ‘Most Important Barriers and Facilitators of HTA Usage in Decision-Making in Europe’. Expert Review of Pharmacoeconomics & Outcomes Research 18, no. 3 (4 May 2018): 297-304. https://doi.org/10.1080/14737167.2018.1421459.
  28. Ciani, Oriana, Carlo Federici, and Rosanna Tarricone. ‘Current and Future Trends in the HTA of Medical Devices’. In XIV Mediterranean Conference on Medical and Biological Engineering and Computing 2016, edited by Efthyvoulos Kyriacou, Stelios Christofides, and Constantinos S. Pattichis, 1345-1348. Paphos, Cyprus: Springer International Publishing, 2016. https://doi.org/10.1007/978-3-319-32703-7_258.
  29. Ciani, Oriana, Bogdan Grigore, and Rod S. Taylor. ‘Development of a Framework and Decision Tool for the Evaluation of Health Technologies Based on Surrogate Endpoint Evidence’. Health Economics 31, no. S1 (2022): 44-72. https://doi.org/10.1002/hec.4524.
  30. Ciani, Oriana, Britni Wilcher, Anoukh van Giessen, and Rod S. Taylor. ‘Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments’. Health Economics 26, no. S1 (2017): 13-29. https://doi.org/10.1002/hec.3479.
  31. Ciani, Oriana, and Claudio Jommi. ‘The Role of Health Technology Assessment Bodies in Shaping Drug Development’. Drug Design, Development and Therapy 8 (10 November 2014): 2273-2281. https://doi.org/10.2147/DDDT.S49935.
  32. Clemens, Timo, Kai Michelsen, and Helmut Brand. ‘Supporting Health Systems in Europe: Added Value of EU Actions’. Health Economics Policy and Law 9, no. 1 (2014): 49-70. https://doi.org/10.1017/S1744133113000273.
  33. Coleman, Carl. ‘Cost-Effectiveness Comes to America: The Promise and Perils of Cost-Effective Analysis in Medication Coverage Decisions’. Georgia State University Law Review 38, no. 3 (1 June 2022): 811.
  34. Curtis, Lesley H., Oriol Sola-Morales, Julien Heidt, Patrick Saunders-Hastings, Laura Walsh, Deborah Casso, Susan Oliveria, et al. ‘Regulatory and HTA Considerations for Development of Real-World Data Derived External Controls’. Clinical Pharmacology & Therapeutics 114, no. 2 (2023): 303-315. https://doi.org/10.1002/cpt.2913.
  35. Cyr, Pascale Renée, Vageesh Jain, Kalipso Chalkidou, Trygve Ottersen, and Unni Gopinathan. ‘Evaluations of Public Health Interventions Produced by Health Technology Assessment Agencies: A Mapping Review and Analysis by Type and Evidence Content’. Health Policy (Amsterdam, Netherlands) 125, no. 8 (August 2021): 1054-1064. https://doi.org/10.1016/j.healthpol.2021.05.009.
  36. De Grove-Valdeyron, Nathalie. ‘Les nouvelles technologies et la politique de santé de l’union européenne’. Lamy Droit de l’Immatériel, 1 October 2014, 108.
  37. Di Costanzo, Caterina. ‘Healthcare Resource Allocation and Priority-Setting. A European Challenge’. European Journal of Health Law 27, no. 2 (2020): 93-114. https://doi.org/10.1163/15718093-12271448.
  38. Drummond, Michael, Oriana Ciani, Giulia Fornaro, Claudio Jommi, Eva Susanne Dietrich, Jaime Espin, Jean Mossman, and Gerard de Pouvourville. ‘How Are Health Technology Assessment Bodies Responding to the Assessment Challenges Posed by Cell and Gene Therapy?’ BMC Health Services Research 23, no. 1 (13 May 2023): 484. https://doi.org/10.1186/s12913-023-09494-5.
  39. Drummond, Michael F., Federico Augustovski, Devarshi Bhattacharyya, Jonathan Campbell, Nathorn Chaiyakanapruk, Yingyao Chen, Rosa Maria Galindo-Suarez, et al. ‘Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report’. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 25, no. 8 (August 2022): 1257-1267. https://doi.org/10.1016/j.jval.2022.02.006.
  40. Eddy, David. ‘Health Technology Assessment and Evidence-Based Medicine: What Are We Talking About?’ Value in Health 12, no. s2 (2009): S6-7. https://doi.org/10.1111/j.1524-4733.2009.00551.x.
  41. Edward N. Brandt, Jr. ‘Technology Assessment, a Private-Public Partnership’. Public Health Reports (1974-) 99, no. 4 (1984): 329-330.
  42. Eichler, Hans-Georg, Brigitte Bloechl-Daum, Eric Abadie, David Barnett, Franz König, and Steven Pearson. ‘Relative Efficacy of Drugs: An Emerging Issue between Regulatory Agencies and Third-Party Payers’. Nature Reviews Drug Discovery 9, no. 4 (April 2010): 277-291. https://doi.org/10.1038/nrd3079.
  43. Eichler, Hans-Georg, Francesco Pignatti, Bruno Flamion, Hubert Leufkens, and Alasdair Breckenridge. ‘Balancing Early Market Access to New Drugs with the Need for Benefit/Risk Data: A Mounting Dilemma’. Nature Reviews Drug Discovery 7, no. 10 (October 2008): 818-826. https://doi.org/10.1038/nrd2664.
  44. Elvidge, Suzanne. ‘EMA’s Parallel Advice Workshop Bridges Regulatory and Reimbursement Divide’. Nature Reviews Drug Discovery 13, no. 1 (1 January 2014): 8-8. https://doi.org/10.1038/nrd4219.
  45. Enzmann, Harald. ‘New Trends and Challenges in the European Regulation of Innovative Medicines’. Regulatory Toxicology and Pharmacology 80 (1 October 2016): 314-320. https://doi.org/10.1016/j.yrtph.2016.05.033.
  46. Ernst, Gisela. ‘What Is Possible and What Is Not? The Development of a Legal Framework for Drug Pricing Mechanisms in the EU’. European Journal of Health Law 26, no. 2 (24 April 2019): 120–40. https://doi.org/10.1163/15718093-12262423.
  47. Ernst, Gisela, and Karl Stöger. ‘Give Due Consideration …: Some Thoughts on Member States’ Obligations Under Article 13 of the HTA Regulation’. European Journal of Health Law 31, no. 2 (13 March 2024): 171-186. https://doi.org/10.1163/15718093-bja10122.
  48. Europe, World Health Organization Regional Office for. ‘Access to New Medicines in Europe: Technical Review of Policy Initiatives and Opportunities for Collaboration and Research’. In Access to New Medicines in Europe: Technical Review of Policy Initiatives and Opportunities for Collaboration and Research, 2015. https://iris.who.int/handle/10665/159405.
  49. Exter, Andre den. ‘Health Care Decision-Making and the Law Health Law’. Jotwell: The Journal of Things We Like (Lots) 2023, no. 4 (2023): 1-2.
  50. Exter, Andre den, Alceste Santuari, and Tomislav Sokol. ‘One Year after the EU Patient Mobility Directive: A Three-Country Analysis | Westlaw UK’. European Law Review 40, no. 2 (2015): 279-293.
  51. Facey, Karen, Antoine Boivin, Javier Gracia, Helle Ploug Hansen, Alessandra Lo Scalzo, Jean Mossman, and Ann Single. ‘Patients’ Perspectives in Health Technology Assessment: A Route to Robust Evidence and Fair Deliberation’. International Journal of Technology Assessment in Health Care 26, no. 3 (July 2010): 334-340. https://doi.org/10.1017/S0266462310000395.
  52. Facey, Karen, Alicia Granados, Gordon Guyatt, Alastair Kent, Nilay Shah, Gert Jan van der Wilt, and Durhane Wong-Rieger. ‘Generating HTA Evidence for Rare Diseases’. International Journal of Technology Assessment in Health Care 30, no. 4 (October 2014): 416-422. https://doi.org/10.1017/S0266462314000464.
  53. Faeh, Andrea. ‘A Just Distribution of Health Care in the Case of Orphan Medicinal Products: Aligning the Interests of European Economic Integration and National Welfare Policy’. European Journal of Social Security 14, no. 1 (2012): 21-40.
  54. Fanourgiakis, John, and Emmanuel Kanoupakis. ‘Health Technology Assessment (HTA): A Brief Introduction of History and the Current Status in the Field of Cardiology under the Economic Crisis’. Journal of Evidence-Based Medicine 8, no. 3 (2015): 161-164. https://doi.org/10.1111/jebm.12171.
  55. Farah, Line, Julie Davaze-Schneider, Tess Martin, Pierre Nguyen, Isabelle Borget, and Nicolas Martelli. ‘Are Current Clinical Studies on Artificial Intelligence-Based Medical Devices Comprehensive Enough to Support a Full Health Technology Assessment? A Systematic Review’. Artificial Intelligence in Medicine 140 (June 2023): 102547. https://doi.org/10.1016/j.artmed.2023.102547.
  56. Faulkner, Sd, M Lee, D Qin, L Morrell, E Xoxi, A Sammarco, S Cammarata, P Russo, L Pani, and R Barker. ‘Pricing and Reimbursement Experiences and Insights in the European Union and the United States: Lessons Learned to Approach Adaptive Payer Pathways’. Clinical Pharmacology & Therapeutics 100, no. 6 (2016): 730–42. https://doi.org/10.1002/cpt.508.
  57. Ferraro, Simona, Elia Mario Biganzoli, Silvana Castaldi, and Mario Plebani. ‘Health Technology Assessment to Assess Value of Biomarkers in the Decision-Making Process’. Clinical Chemistry and Laboratory Medicine (CCLM) 60, no. 5 (1 April 2022): 647-654. https://doi.org/10.1515/cclm-2021-1291.
  58. Fletcher, Christine, Christy Chuang-Stein, Marie-Ange Paget, Carol Reid, and Neil Hawkins. ‘Subgroup Analyses in Cost-Effectiveness Analyses to Support Health Technology Assessments’. Pharmaceutical Statistics 13, no. 4 (2014): 265-274. https://doi.org/10.1002/pst.1626.
  59. Fontrier, Anna-Maria, Erica Visintin, and Panos Kanavos. ‘Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries’. PharmacoEconomics - Open 6, no. 3 (1 May 2022): 315-328. https://doi.org/10.1007/s41669-021-00311-5.
  60. ‘Future of Innovation in Medicine: Incentives for New Medical Treatments and Global Health: Transcript Symposium 2017’. Washington Journal of Law, Technology & Arts 12, no. 3 (2017 2016): 293-448.
  61. Gagnon, Marie-Pierre, Mylène Tantchou Dipankui, Thomas G. Poder, Julie Payne-Gagnon, Gisèle Mbemba, and Valentina Beretta. ‘Patient and Public Involvement in Health Technology Assessment: Update of a Systematic Review of International Experiences’. International Journal of Technology Assessment in Health Care 37, no. 1 (January 2021): e36. https://doi.org/10.1017/S0266462321000064.
  62. Gagnon, Marie-Pierre, Marie Desmartis, Dolorès Lepage-Savary, Johanne Gagnon, Michèle St-Pierre, Marc Rhainds, Renald Lemieux, Francois-Pierre Gauvin, Hugo Pollender, and France Légaré. ‘Introducing Patients’ and the Public’s Perspectives to Health Technology Assessment: A Systematic Review of International Experiences’. International Journal of Technology Assessment in Health Care 27, no. 1 (January 2011): 31-42. https://doi.org/10.1017/S0266462310001315.
  63. Gagnon, Marie-Pierre, Marie Desmartis, Thomas Poder, and William Witteman. ‘Effects and Repercussions of Local/Hospital-Based Health Technology Assessment (HTA): A Systematic Review’. Systematic Reviews 3, no. 1 (28 October 2014): 129. https://doi.org/10.1186/2046-4053-3-129.
  64. Garrido, Marcial Velasco. Health Technology Assessment and Health Policy-Making in Europe: Current Status, Challenges, and Potential. WHO Regional Office Europe, 2008.
  65. Gibson, Shannon, and Trudo Lemmens. ‘The Promise and Peril of Adapting the Regulatory System to the Pharmacogenomic Context’. McGill Journal of Law and Health 8, no. 2 (2015 2014): S145-230.
  66. Greaves, Ronda, Larry Kricka, Damien Gruson, Maurizio Ferrari, Helen Martin, Tze Ping Loh, Sergio Bernardini, and on behalf of the IFCC Emerging Technologies Division. ‘Toolkit for Emerging Technologies in Laboratory Medicine’. Clinical Chemistry and Laboratory Medicine (CCLM) 61, no. 12 (1 November 2023): 2102-214. https://doi.org/10.1515/cclm-2023-0571.
  67. Grigore, Bogdan, Oriana Ciani, Florian Dams, Carlo Federici, Saskia de Groot, Meilin Möllenkamp, Stefan Rabbe, Kosta Shatrov, Antal Zemplenyi, and Rod S. Taylor. ‘Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines’. PharmacoEconomics 38, no. 10 (1 October 2020): 1055-1070. https://doi.org/10.1007/s40273-020-00935-1.
  68. Hailey, David. ‘Development of the International Network of Agencies for Health Technology Assessment’. International Journal of Technology Assessment in Health Care 25, no. S1 (July 2009): 24–27. https://doi.org/10.1017/S0266462309090370.
  69. Hanney, Stephen R., Miguel A. Gonzalez-Block, Martin J. Buxton, and Maurice Kogan. ‘The Utilisation of Health Research in Policy-Making: Concepts, Examples and Methods of Assessment’. Health Research Policy and Systems 1, no. 1 (13 January 2003): 2. https://doi.org/10.1186/1478-4505-1-2.
  70. Hao, Yanni, and Adrian Thomas. ‘Health Technology Assessment and Comparative Effectiveness Research: A Pharmaceutical Industry Perspective’. Expert Review of Pharmacoeconomics & Outcomes Research 13, no. 4 (August 2013): 447-454. https://doi.org/10.1586/14737167.2013.815401.
  71. Harker, Julie, and Jos Kleijnen. ‘What Is a Rapid Review? A Methodological Exploration of Rapid Reviews in Health Technology Assessments’. International Journal of Evidence-Based Healthcare 10, no. 4 (2012): 397-410. https://doi.org/10.1111/j.1744-1609.2012.00290.x.
  72. Have, Henk ten. ‘Ethical Perspectives on Health Technology Assessment’. International Journal of Technology Assessment in Health Care 20, no. 1 (January 2004): 71-76. https://doi.org/10.1017/S0266462304000819.
  73. Heintz, Emelie, Andreas Gerber-Grote, Salah Ghabri, Francoise F. Hamers, Valentina Prevolnik Rupel, Renata Slabe-Erker, Thomas Davidson, and Work Package 7 EUnetHTA Joint Action 2 Subgroup 3. ‘Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries’. PharmacoEconomics 34, no. 1 (1 January 2016): 59-76. https://doi.org/10.1007/s40273-015-0328-1.
  74. Hemminki, Elina, David Hailey, and Meri Koivusalo. ‘The Courts -- A Challenge to Health Technology Assessment’. Science 285, no. 5425 (1999): 203-204.
  75. Henshall, Chris, Wija Oortwijn, Andrew Stevens, Alicia Granados, and David Banta. ‘Priority Setting for Health Technology Assessment: Theoretical Considerations and Practical Approaches: A Paper Produced by the Priority Setting Subgroup of the EUR-ASSESS Project’. International Journal of Technology Assessment in Health Care 13, no. 2 (April 1997): 144-185. https://doi.org/10.1017/S0266462300010357.
  76. Hirtz, Blandine. ‘Potentiel et limites d’une évaluation technologique des produits de santé à l’échelle européenne : l’évaluation des technologies de santé (ETS) européenne face à ses contradictions’. Revue française des affaires sociales, no. 3 (2018): 297-305. https://doi.org/10.3917/rfas.183.0297.
  77. Hodges, Christopher. ‘Regulating Risk or Advancing Therapies - Regulation and Sustainability of Medicines in a Cash-Limited Economy’. European Business Law Review 19, no. 2 (2008): 365-386.
  78. Hofmann, Bjørn, Ken Bond, and Lars Sandman. ‘Evaluating Facts and Facting Evaluations: On the Fact-Value Relationship in HTA’. Journal of Evaluation in Clinical Practice 24, no. 5 (2018): 957-965. https://doi.org/10.1111/jep.12920.
  79. Hogervorst, Milou Amber, Rick Vreman, Inkatuuli Heikkinen, Indranil Bagchi, Inaki Gutierrez-Ibarluzea, Bettina Ryll, Hans-Georg Eichler, et al. ‘Uncertainty Management in Regulatory and Health Technology Assessment Decision-Making on Drugs: Guidance of the HTAi-DIA Working Group’. International Journal of Technology Assessment in Health Care 39, no. 1 (January 2023): e40. https://doi.org/10.1017/S0266462323000375.
  80. Houyez, Francois. ‘High Price Medicines and Health Budgets: The Role of Patients’ and Consumers’ Organisations Can Play Special Issue: Innovative Medicine and Research: Ethical, Legal and Regulatory Issues: News & Views’. European Journal of Health Law 27, no. 3 (2020): 309-323. https://doi.org/10.1163/15718093-BJA10008.
  81. Hoxhaj, Ilda, Carolina Castagna, Giovanna Elisa Calabrò, and Stefania Boccia. ‘HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations’. Frontiers in Public Health 10 (10 February 2022). https://doi.org/10.3389/fpubh.2022.795763.
  82. Huls, Samare P. I., Chiara L. Whichello, Job van Exel, Carin A. Uyl-de Groot, and Esther W. de Bekker-Grob. ‘What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges’. Value in Health 22, no. 11 (1 November 2019): 1318-1328. https://doi.org/10.1016/j.jval.2019.04.1930.
  83. Hunter, Amy, Karen Facey, Victoria Thomas, David Haerry, Kay Warner, Ingrid Klingmann, Matthew May, and Wolf See. ‘EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment’. Frontiers in Medicine 5 (6 September 2018). https://doi.org/10.3389/fmed.2018.00231.
  84. Hutton, John, Paul Trueman, and Karen Facey. ‘Harmonization of Evidence Requirements for Health Technology Assessment in Reimbursement Decision Making’. International Journal of Technology Assessment in Health Care 24, no. 4 (October 2008): 511-517. https://doi.org/10.1017/S0266462308080677.
  85. Ibargoyen-Roteta, Nora, Lorea Galnares-Cordero, Gaizka Benguria-Arrate, Kelly Rocío Chacón-Acevedo, María Paula Gutiérrez-Sepulveda, Eduardo Low-Padilla, Ilich Herbert De La Hoz-Siegler, et al. ‘A Systematic Review of the Early Dialogue Frameworks Used within Health Technology Assessment and Their Actual Adoption from HTA Agencies’. Frontiers in Public Health 10 (6 October 2022). https://doi.org/10.3389/fpubh.2022.942230.
  86. IJzerman, Maarten J., Hendrik Koffijberg, Elisabeth Fenwick, and Murray Krahn. ‘Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature’. PharmacoEconomics 35, no. 7 (1 July 2017): 727-740. https://doi.org/10.1007/s40273-017-0509-1.
  87. Iskrov, Georgi, Tsonka Miteva-Katrandzhieva, and Rumen Stefanov. ‘Health Technology Assessment and Appraisal of Therapies for Rare Diseases’. Advances in Experimental Medicine and Biology 1031 (2017): 221-231. https://doi.org/10.1007/978-3-319-67144-4_13.
  88. Jacobs, Esther, Sunya-Lee Antoine, Barbara Prediger, Edmund Neugebauer, and Michaela Eikermann. ‘Defining the Relevant Outcome Measures in Medical Device Assessments: An Analysis of the Definition Process in HTA’. International Journal of Technology Assessment in Health Care 33, no. 1 (January 2017): 84-92. https://doi.org/10.1017/S0266462317000216.
  89. Jiu, Li, Junfeng Wang, Francisco Javier Somolinos-Simón, Jose Tapia-Galisteo, Gema García-Sáez, Mariaelena Hernando, Xinyu Li, Rick A. Vreman, Aukje K. Mantel-Teeuwisse, and Wim G. Goettsch. ‘A Literature Review of Quality Assessment and Applicability to HTA of Risk Prediction Models of Coronary Heart Disease in Patients with Diabetes’. Diabetes Research and Clinical Practice 209 (1 March 2024): 111574. https://doi.org/10.1016/j.diabres.2024.111574.
  90. Jong, Amos J. de, Nadi Shahid, Mira G. P. Zuidgeest, Yared Santa-Ana-Tellez, Milou Hogervorst, Wim Goettsch, Hamidou Traore, Anthonius de Boer, and Helga Gardarsdottir. ‘Opportunities and Challenges for Decentralized Clinical Trial Approaches: European Health Technology Assessment Perspective’. Value in Health 27, no. 3 (1 March 2024): 294-300. https://doi.org/10.1016/j.jval.2023.11.006.
  91. Jönsson, Bengt. ‘Bringing in Health Technology Assessment and Cost-Effectiveness Considerations at an Early Stage of Drug Development’. Molecular Oncology 9, no. 5 (2015): 1025-1033. https://doi.org/10.1016/j.molonc.2014.10.009.
  92. Julian, Elaine, Mira Pavlovic, Oriol Sola-Morales, Fabrizio Gianfrate, Mondher Toumi, Heiner C. Bucher, Christian Dierks, et al. ‘Shaping a Research Agenda to Ensure a Successful European Health Technology Assessment: Insights Generated during the Inaugural Convention of the European Access Academy’. Health Economics Review 12, no. 1 (5 November 2022): 54. https://doi.org/10.1186/s13561-022-00402-x.
  93. Kalf, Rachel R. J., Rick A. Vreman, Diana M.J. Delnoij, Marcel L. Bouvy, and Wim G. Goettsch. ‘Bridging the Gap: Can International Consortium of Health Outcomes Measurement Standard Sets Align Outcomes Accepted for Regulatory and Health Technology Assessment Decision-Making of Oncology Medicines’. Pharmacology Research & Perspectives 9, no. 2 (2021): e00742. https://doi.org/10.1002/prp2.742.
  94. Kaló, Zoltán, and Zoltán Vokó. ‘Health Technology Assessment: A European Collaboration’. Expert Review of Pharmacoeconomics & Outcomes Research 11, no. 1 (1 February 2011): 41-43. https://doi.org/10.1586/erp.10.90.
  95. Kammerer, Mariette. ‘La Haute Autorité de santé annonce de nouveaux outils pour encourager la participation des usagers à ses travaux’. Protection Sociale Informations, no. No 1337 (22 November 2022). 
  96. Kanis, John A., and Mickaël Hiligsmann. ‘The Application of Health Technology Assessment in Osteoporosis’. Best Practice & Research Clinical Endocrinology & Metabolism, Osteoporosis: Efficacy, Safety and Cost-Effectiveness of Established and Novel Therapies, 28, no. 6 (1 December 2014): 895-910. https://doi.org/10.1016/j.beem.2014.04.001.
  97. Karnon, Jonathan, Laura Edney, and Hossein Afzali. ‘The Political Economy of the Assessment of Value of New Health Technologies’. Journal of Health Services Research & Policy 23, no. 2 (2018): 116-122. http://dx.doi.org/10.1177/1355819617751816.
  98. Kennedy-Martin, Matthew, Bernhard Slaap, Michael Herdman, Mandy van Reenen, Tessa Kennedy-Martin, Wolfgang Greiner, Jan Busschbach, and Kristina S. Boye. ‘Which Multi-Attribute Utility Instruments Are Recommended for Use in Cost-Utility Analysis? A Review of National Health Technology Assessment (HTA) Guidelines’. European Journal of Health Economics 21, no. 8 (November 2020): 1245-1257. https://doi.org/10.1007/s10198-020-01195-8.
  99. Klein, Philip, Hedwig Blommestein, Maiwenn Al, Benedetta Pongiglione, Aleksandra Torbica, and Saskia de Groot. ‘Real-World Evidence in Health Technology Assessment of High-Risk Medical Devices: Fit for Purpose?’ Health Economics 31, no. S1 (2022): 10-24. https://doi.org/10.1002/hec.4575.
  100. Köhler, Michael, Susanne Haag, Katharina Biester, Anne Catharina Brockhaus, Natalie McGauran, Ulrich Grouven, Heike Kölsch, et al. ‘Information on New Drugs at Market Entry: Retrospective Analysis of Health Technology Assessment Reports versus Regulatory Reports, Journal Publications, and Registry Reports’. BMJ: British Medical Journal 350 (2015). https://doi.org/0.1136/bmj.h796.
  101. Kolasa, Katarzyna, Zoltan Kalo, Vladimir Zah, and Tomas Dolezal. ‘Role of Health Technology Assessment in the Process of Implementation of the EU Transparency Directive: Relevant Experience from Central Eastern European Countries’. Expert Review of Pharmacoeconomics & Outcomes Research 12, no. 3 (1 June 2012): 283-287. https://doi.org/10.1586/erp.12.12.
  102. Lakdawalla, Darius N., Jalpa A. Doshi, Louis P. Garrison, Charles E. Phelps, Anirban Basu, and Patricia M. Danzon. ‘Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]’. Value in Health 21, no. 2 (1 February 2018): 131-139. https://doi.org/10.1016/j.jval.2017.12.007.
  103. Langley, Paul C. ‘Imaginary Worlds: The European Network for Health Technology Assessment (EUnetHTA) Recommendations for Health Economic Evaluations’. INNOVATIONS in Pharmacy 7, no. 3 (24 August 2016). https://doi.org/10.24926/iip.v7i3.446.
  104. Leckenby, Emily, Dalia Dawoud, Jacoline Bouvy, and Páll Jónsson. ‘The Sandbox Approach and Its Potential for Use in Health Technology Assessment: A Literature Review’. Applied Health Economics and Health Policy 19, no. 6 (1 November 2021): 857-869. https://doi.org/10.1007/s40258-021-00665-1.
  105. Lehoux, Pascale, Myriam Hivon, Jean-Louis Denis, and Stephanie Tailliez. ‘What Medical Specialists like and Dislike about Health Technology Assessment Reports’. Journal of Health Services Research & Policy 14, no. 4 (2009): 197-203. https://doi.org/10.1258/jhsrp.2009.00815.
  106. Lloyd-Williams, Huw, and Dyfrig A. Hughes. ‘A Systematic Review of Economic Evaluations of Advanced Therapy Medicinal Products’. British Journal of Clinical Pharmacology 87, no. 6 (2021): 2428-2443. https://doi.org/10.1111/bcp.14275.
  107. Loblova, Olga. ‘Three Worlds of Health Technology Assessment: Explaining Patterns of Diffusion of HTA Agencies in Europe’. Health Economics Policy and Law 11, no. 3 (16 December 2015): 253-274. https://doi.org/doi:10.1017/S1744133115000444.
  108. Löblová, Olga. ‘What Has Health Technology Assessment Ever Done for Us?’ Journal of Health Services Research & Policy 23, no. 2 (2018): 134-136. https://doi.org/10.1177/1355819617725545.
  109. Löblová, Olga, Trayan Trayanov, Marcell Csanádi, and Piotr Ozierański. ‘The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review’. Value in Health 23, no. 1 (1 January 2020): 3-9. https://doi.org/10.1016/j.jval.2019.07.016.
  110. Low, Eunice, Joëlle André-Vert, Gaëlle Fanelli, and Margaret Galbraith. ‘International Overview of Health Technology Assessment Training Tools and Materials for Patients and Consumers’. International Journal of Technology Assessment in Health Care 39, no. 1 (January 2023): e61. https://doi.org/10.1017/S0266462323000533.
  111. Luce, Bryan R., Michael Drummond, Bengt Jönsson, Peter J. Neumann, J. Sanford Schwartz, Uwe Siebert, and Sean D. Sullivan. ‘EBM, HTA, and CER: Clearing the Confusion’. The Milbank Quarterly 88, no. 2 (2010): 256-276. https://doi.org/10.1111/j.1468-0009.2010.00598.x.
  112. Makady, Amr, Renske ten Ham, Anthonius de Boer, Hans Hillege, Olaf Klungel, and Wim Goettsch. ‘Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies’. Value in Health 20, no. 4 (1 April 2017): 520-532. https://doi.org/10.1016/j.jval.2016.12.003.
  113. Maignen, François, Leeza Osipenko, Pilar Pinilla-Dominguez, and Emily Crowe. ‘Outcomes of Early Health Technology Assessment Dialogues in Medicinal Product Development’. Nature Reviews Drug Discovery 16, no. 2 (1 February 2017): 79-79. https://doi.org/10.1038/nrd.2016.286.
  114. Mason, Robert J., Karlee M. Searle, Yvonne Bombard, Amanda Rahmadian, Alexandra Chambers, Helen Mai, Marjorie Morrison, Kelvin K. W. Chan, and Katarzyna J. Jerzak. ‘Evaluation of the Impact of Patient Involvement in Health Technology Assessments: A Scoping Review’. International Journal of Technology Assessment in Health Care 36, no. 3 (June 2020): 217-223. https://doi.org/10.1017/S0266462320000239.
  115. Martelli, Francesco, Giuseppe La Torre, Elena Di Ghionno, Tommaso Staniscia, Massimo Neroni, Americo Cicchetti, Konrade Von Bremen, Walter Ricciardi, and NI-HTA Collaborative Group. ‘Health Technology Assessment Agencies: An International Overview of Organizational Aspects’. International Journal of Technology Assessment in Health Care 23, no. 4 (October 2007): 414-424. https://doi.org/10.1017/S026646230707064X.
  116. Martelli, Nicolas, Anne-Sophie Lelong, Patrice Prognon, and Judith Pineau. ‘Hospital-Based Health Technology Assessment for Innovative Medical Devices in University Hospitals and the Role of Hospital Pharmacists: Learning from International Experience’. International Journal of Technology Assessment in Health Care 29, no. 2 (April 2013): 185-191. https://doi.org/10.1017/S0266462313000019.
  117. May, Carl. ‘Mobilising Modern Facts: Health Technology Assessment and the Politics of Evidence’. Sociology of Health & Illness 28, no. 5 (2006): 513-532. https://doi.org/10.1111/j.1467-9566.2006.00505.x.
  118. McAuslane, Neil, Lawrence Liberti, and Patricia Connelly. ‘The Confluence of Accelerated Regulatory and Health Technology Assessment Access Pathways’. Clinical Pharmacology & Therapeutics 105, no. 4 (2019): 935-942. https://doi.org/10.1002/cpt.1315.
  119. Migliore, Antonio. ‘Towards a Regulation of HTA in Europe: The Proposal from the European Commission’. Expert Review of Medical Devices 16, no. 1 (2 January 2019): 1-2. https://doi.org/10.1080/17434440.2019.1557047.
  120. Mills, Mackenzie, and Panos Kanavos. ‘How Do HTA Agencies Perceive Conditional Approval of Medicines? Evidence from England, Scotland, France and Canada’. Health Policy 126, no. 11 (1 November 2022): 1130-1143. https://doi.org/10.1016/j.healthpol.2022.08.005.
  121. Ming, Jian, Yunzhen He, Yi Yang, Min Hu, Xinran Zhao, Jun Liu, Yang Xie, Yan Wei, and Yingyao Chen. ‘Health Technology Assessment of Medical Devices: Current Landscape, Challenges, and a Way Forward’. Cost Effectiveness and Resource Allocation 20, no. 1 (5 October 2022): 54. https://doi.org/10.1186/s12962-022-00389-6.
  122. Moharra, Montse, Mireia Espallargues, Nadine Kubesch, Maria-Dolors Estrada, Antoni Parada, Hindrik Vondeling, Alessandra Lo Scalzo, et al. ‘Systems to Support Health Technology Assessment (HTA) in Member States of the European Union with Limited Institutionalization of HTA’. International Journal of Technology Assessment in Health Care 25 Suppl 2 (December 2009): 75-83. https://doi.org/10.1017/S0266462309990717.
  123. Monleón, Clara, Hans-Martin Späth, Carlos Crespo, Claude Dussart, and Mondher Toumi. ‘Systematic Literature Review on Implicit Factors Influencing the HTA Deliberative Processes in Europe’. Journal of Market Access & Health Policy 10, no. 1 (December 2022): 2094047. https://doi.org/10.1080/20016689.2022.2094047.
  124. Moseley, Jane, Spiros Vamvakas, Michael Berntgen, Alison Cave, Xavier Kurz, Peter Arlett, Virginia Acha, et al. ‘Regulatory and Health Technology Assessment Advice on Postlicensing and Postlaunch Evidence Generation Is a Foundation for Lifecycle Data Collection for Medicines’. British Journal of Clinical Pharmacology 86, no. 6 (2020): 1034-1051. https://doi.org/10.1111/bcp.14279.
  125. Moretti, Francesco, Fabrice Ruiz, Fedele Bonifazi, Elena Pizzo, Jenny M. Kindblom, and the c4c HTA expert Group. ‘Health Technology Assessment of Paediatric Medicines: European Landscape, Challenges and Opportunities inside the Conect4children Project’. British Journal of Clinical Pharmacology 88, no. 12 (2022): 5052-5059. https://doi.org/10.1111/bcp.15190.
  126. Nemzoff, Cassandra, Hiral A. Shah, Lieke Fleur Heupink, Lydia Regan, Srobana Ghosh, Morgan Pincombe, Javier Guzman, Sedona Sweeney, Francis Ruiz, and Anna Vassall. ‘Adaptive Health Technology Assessment: A Scoping Review of Methods’. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 26, no. 10 (October 2023): 1549-1557. https://doi.org/10.1016/j.jval.2023.05.017.
  127. Neumann, Peter J. ‘Lessons for Health Technology Assessment: It Is Not Only about the Evidence’. Value in Health 12, no. s2 (2009): S45–48. https://doi.org/10.1111/j.1524-4733.2009.00558.x.
  128. Ng, T., J. Ziomek, C. Delaitre-Bonnin, and M. W. Bending. ‘A Review of the Impact of Integrated Scientific Advice for the Optimisation of Evidence Generation for HTA Appraisals’. Value in Health 21 (1 October 2018): S197. https://doi.org/10.1016/j.jval.2018.09.1170.
  129. Nicod, Elena, Laia Maynou, Erica Visintin, and John Cairns. ‘Why Do Health Technology Assessment Drug Reimbursement Recommendations Differ between Countries? A Parallel Convergent Mixed Methods Study’. Health Economics Policy and Law 15, no. 3 (2020): 386-402. https://doi.org/doi:10.1017/S1744133119000239.
  130. Nielsen, Camilla PalmhøJ, Tina Maria Funch, and Finn Børlum Kristensen. ‘Health Technology Assessment: Research Trends and Future Priorities in Europe’. Journal of Health Services Research & Policy 16, no. 2_suppl (1 July 2011): 6-15. https://doi.org/10.1258/jhsrp.2011.011050.
  131. Nooten, Floortje van, Stefan Holmstrom, Julia Green, Ingela Wiklund, Isaac A. O. Odeyemi, and Teresa K. Wilcox. ‘Health Economics and Outcomes Research within Drug Development: Challenges and Opportunities for Reimbursement and Market Access within Biopharma Research’. Drug Discovery Today 17, no. 11 (1 June 2012): 615-622.https://doi.org/10.1016/j.drudis.2012.01.021.
  132. Normand, Charles. ‘Setting Priorities in and for End-of-Life Care: Challenges in the Application of Economic Evaluation’. Health Economics Policy and Law 7, no. 4 (2012): 431-440. https://doi.org/10.1017/S1744133112000229.
  133. Novaes, Hillegonda Maria Dutilh, and Patrícia Coelho de Soárez. ‘Health Technology Assessment (HTA) Organizations: Dimensions of the Institutional and Political Framework’. Cadernos de Saúde Pública 32 (3 November 2016): e00022315. https://doi.org/10.1590/0102-311X00022315.
  134. Novielli, Nicola, Nicola J. Cooper, Keith R. Abrams, and Alex J. Sutton. ‘How Is Evidence on Test Performance Synthesized for Economic Decision Models of Diagnostic Tests? A Systematic Appraisal of Health Technology Assessments in the UK Since 1997’. Value in Health 13, no. 8 (2010): 952-957. https://doi.org/10.1111/j.1524-4733.2010.00762.x.
  135. O’Donnell, John C., Sissi V. Pham, Chris L. Pashos, David W. Miller, and Marilyn Dix Smith. ‘Health Technology Assessment: Lessons Learned from Around the World—An Overview’. Value in Health 12, no. s2 (2009): S1-5. https://doi.org/10.1111/j.1524-4733.2009.00550.x.
  136. Ofori-Asenso, Richard, Christine E. Hallgreen, and Marie Louise De Bruin. ‘Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges’. Frontiers in Medicine 7 (16 October 2020). https://doi.org/10.3389/fmed.2020.582634.
  137. O’Hara, Jamie, Peter J. Neumann, and the International Haemophilia Access Strategy Council. ‘Health Technology Assessment for Gene Therapies in Haemophilia’. Haemophilia 28, no. S2 (2022): 19-26. https://doi.org/10.1111/hae.14413.
  138. Olberg, Britta, Sabine Fuchs, Dimitra Panteli, Matthias Perleth, and Reinhard Busse. ‘Scientific Evidence in Health Technology Assessment Reports: An In-Depth Analysis of European Assessments on High-Risk Medical Devices’. Value in Health 20, no. 10 (1 December 2017): 1420-1426. https://doi.org/10.1016/j.jval.2017.05.011.
  139. Oliveira, Mónica D., Inês Mataloto, and Panos Kanavos. ‘Multi-Criteria Decision Analysis for Health Technology Assessment: Addressing Methodological Challenges to Improve the State of the Art’. The European Journal of Health Economics 20, no. 6 (1 August 2019): 891-918. https://doi.org/10.1007/s10198-019-01052-3.
  140. Oliver, Adam, Elias Mossialos, and Ray Robinson. ‘Health Technology Assessment and Its Influence on Health-Care Priority Setting’. International Journal of Technology Assessment in Health Care 20, no. 1 (January 2004): 1-10. https://doi.org/10.1017/S026646230400073X.
  141. O’Reilly, Daria, Kaitryn Campbell, Ron Goeree, and Programs for Assessment of Technology in Health Research Institute. ‘Basics of Health Technology Assessment’. Methods in Molecular Biology (Clifton, N.J.) 473 (2009): 263-283. https://doi.org/10.1007/978-1-59745-385-1_16.
  142. O’Rourke, Brian, Wija Oortwijn, and Tara Schuller. ‘The New Definition of Health Technology Assessment: A Milestone in International Collaboration’. International Journal of Technology Assessment in Health Care 36, no. 3 (June 2020): 187-190. https://doi.org/10.1017/S0266462320000215.
  143. Overbeeke, Eline van, Sissel Michelsen, Mondher Toumi, Hilde Stevens, Mark Trusheim, Isabelle Huys, and Steven Simoens. ‘Market Access of Gene Therapies across Europe, USA, and Canada: Challenges, Trends, and Solutions’. Drug Discovery Today 26, no. 2 (1 February 2021): 399-415. https://doi.org/10.1016/j.drudis.2020.11.024.
  144. Ozieranski, Piotr, Olga Loblova, Natalia Nicholls, Marcell Csanadi, Zoltan Kalo, Martin McKee, and Lawrence King. ‘Transparency in Practice: Evidence from Verification Analyses Issued by the Polish Agency for Health Technology Assessment in 2012-2015’. Health Economics Policy and Law 14, no. 2 (2018): 182-204. https://doi.org/doi:10.1017/S1744133117000342.
  145. Paget, Marie-Ange, Christy Chuang-Stein, Christine Fletcher, and Carol Reid. ‘Subgroup Analyses of Clinical Effectiveness to Support Health Technology Assessments’. Pharmaceutical Statistics 10, no. 6 (2011): 532-538. https://doi.org/10.1002/pst.531.
  146. Parisi, Thomas J. ‘How Much Did You Pay For You Heart: Is a Centralized Entity Performing Health Technology Assessment with Cost-Effectiveness Analysis the Answer to the Rising Costs of Health Care Developments In Science and Technology Law’. Jurimetrics 49, no. 3 (2009 2008): 285-316.
  147. Paweł Kawalec, Magdalena Mrożek-Gąsiorowska, and Ewa Stawowczyk. ‘Health Technology Assessment of Medical Devices’. Zdrowie Publiczne i Zarządzanie 16, no. 3 (2018): 187-194. https://doi.org/10.4467/20842627OZ.18.021.10434.
  148. Pecchia, L., N. Pallikarakis, R. Magjarevic, and E. Iadanza. ‘Health Technology Assessment and Biomedical Engineering: Global Trends, Gaps and Opportunities’. Medical Engineering & Physics, Special issue to commemorate the 40th anniversary of Medical Engineering & Physics, 72 (1 October 2019): 19-26. https://doi.org/10.1016/j.medengphy.2019.08.008.
  149. Penton, Hannah, Sayeli Jayade, Santhani Selveindran, Marieke Heisen, Christophe Piketty, Liliana Ulianov, Zarif K. Jabbar-Lopez, Jonathan I. Silverberg, and Jorge Puelles. ‘Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials’. Dermatology and Therapy 13, no. 11 (1 November 2023): 2549-2571. https://doi.org/10.1007/s13555-023-01038-3.
  150. Perry, Seymour, and Mae Thamer. ‘Evaluation of Health Care Technologies in the United States Compared to Canada and European Countries’. Journal of Public Health Policy 20, no. 2 (1999): 168-191. https://doi.org/10.2307/3343210.
  151. Pieper, Dawid, Sunya-Lee Antoine, Jana-Carina Morfeld, Tim Mathes, and Michaela Eikermann. ‘Methodological Approaches in Conducting Overviews: Current State in HTA Agencies’. Research Synthesis Methods 5, no. 3 (2014): 187-199. https://doi.org/10.1002/jrsm.1107.
  152. Pinho-Gomes, Ana-Catarina, James Stone, Toni Shaw, Andrea Heath, Jane Cowl, Laura Norburn, Victoria Thomas, and Sarah Scott. ‘Values, Principles, Strategies, and Frameworks Underlying Patient and Public Involvement in Health Technology Assessment and Guideline Development: A Scoping Review’. International Journal of Technology Assessment in Health Care 38, no. 1 (3 June 2022): e46. https://doi.org/10.1017/S0266462322000289.
  153. Pitini, Erica, Corrado De Vito, Carolina Marzuillo, Elvira D’Andrea, Annalisa Rosso, Antonio Federici, Emilio Di Maria, and Paolo Villari. ‘How Is Genetic Testing Evaluated? A Systematic Review of the Literature’. European Journal of Human Genetics 26, no. 5 (May 2018): 605-615. https://doi.org/10.1038/s41431-018-0095-5.
  154. Planel, Maurice-Pierre. ‘L’alliance pancanadienne pharmaceutique : une voie à suivre pour une gouvernance européenne renforcée du prix des médicaments ?’ RDSS / Dalloz, no. 6 (2020): 1097-1112.
  155. Qiu, Tingting, Michal Pochopien, Shuyao Liang, Gauri Saal, Ewelina Paterak, Justyna Janik, and Mondher Toumi. ‘Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment’. Frontiers in Public Health 10 (2022): 773629. https://doi.org/10.3389/fpubh.2022.773629.
  156. Raad, Angie, Maria Rizzo, Katherine Appiah, Isabella Kearns, and Luis Hernandez. ‘Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review’. PharmacoEconomics, 15 March 2024. https://doi.org/10.1007/s40273-024-01362-2.
  157. Raftery, J., S. Hanley, T. Greenhalgh, M. Glover, and A. Blotch-Jones. ‘Models and Applications for Measuring the Impact of Health Research: Update of a Systematic Review for the Health Technology Assessment Programme.’ Health Technology Assessment 20, no. 76 (2016). https://ora.ox.ac.uk/objects/uuid:499b0e0b-8e58-49cf-a077-b208ecb886ac.
  158. Rand, Leah Z., and Aaron S. Kesselheim. ‘An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles’. Journal of Law, Medicine and Ethics 48, no. 3 (2020): 583-594. https://doi.org/DOI: 10.1177/1073110520958885.
  159. Rejon-Parrilla, Juan Carlos, Jaime Espin, and David Epstein. ‘How Innovation Can Be Defined, Evaluated and Rewarded in Health Technology Assessment’. Health Economics Review 12, no. 1 (3 January 2022): 1. https://doi.org/10.1186/s13561-021-00342-y.
  160. Rosenkötter, N., H. Vondeling, I. Blancquaert, O.C.L. Mekel, F.B. Kristensen, and A. Brand. ‘The Contribution of Health Technology Assessment, Health Needs Assessment, and Health Impact Assessment to the Assessment and Translation of Technologies in the Field of Public Health Genomics’. Public Health Genomics 14, no. 1 (2011): 43-52. http://dx.doi.org/10.1159%2F000318317.
  161. Rowen, Donna, Ismail Azzabi Zouraq, Helene Chevrou-Severac, and Ben van Hout. ‘International Regulations and Recommendations for Utility Data for Health Technology Assessment’. PharmacoEconomics 35, no. 1 (1 December 2017): 11-19. https://doi.org/10.1007/s40273-017-0544-y.
  162. Rtveladze, K., S. Kamra, S. Gogna, and J. Gaultney. ‘Will the New EU HTA Regulations Increase the Methodological Requirements to Conducting Systematic Literature Reviews of Clinical Evidence?’ Value in Health 25, no. 12 (1 December 2022): S310. https://doi.org/10.1016/j.jval.2022.09.1531.
  163. Sacchini, Dario, Andrea Virdis, Pietro Refolo, Maddalena Pennacchini, and Ignacio Carrasco de Paula. ‘Health Technology Assessment (HTA): Ethical Aspects Scientific Contribution’. Medicine, Health Care and Philosophy 12, no. 4 (9 June 2009): 453-458. https://doi.org/DOI 10.1007/s 11019-009-9206-y.
  164. Schmidt, Harald, and Julia Kreis. ‘Lessons from Abroad’. The Hastings Center Report 39, no. 6 (2009): 20-22.
  165. Schnell-Inderst, Petra, Julia Mayer, Jörg Lauterberg, Theresa Hunger, Marjan Arvandi, Annette Conrads-Frank, Anna Nachtnebel, Claudia Wild, and Uwe Siebert. ‘Health Technology Assessment of Medical Devices: What Is Different? An Overview of Three European Projects’. Zeitschrift Für Evidenz, Fortbildung Und Qualität Im Gesundheitswesen, Evidenz-informierte Entscheidungen in Österreich, 109, no. 4 (1 January 2015): 309-318. https://doi.org/10.1016/j.zefq.2015.06.011.
  166. Schokkaert, Erik. ‘How to Introduce More (or Better) Ethical Arguments in HTA?’ International Journal of Technology Assessment in Health Care 31, no. 3 (January 2015): 111-112. https://doi.org/10.1017/S0266462315000306.
  167. Schrama, Reini, Dorte Sindbjerg Martinsen, and Ellen Mastenbroek. ‘Networked Health Cooperation in the European Union: Horizontal or Hierarchical?’ JCMS: Journal of Common Market Studies 60, no. 5 (September 2022): 1488-1510. https://doi.org/10.1111/jcms.13327.
  168. Sculpher, Mark, Michael Drummond, and Martin Buxton. ‘The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment’. Journal of Health Services Research & Policy 2, no. 1 (1997): 26-30.
  169. Segur-Ferrer, Joan, Carolina Moltó-Puigmartí, Roland Pastells-Peiró, and Rosa Maria Vivanco-Hidalgo. ‘Methodological Frameworks and Dimensions to Be Considered in Digital Health Technology Assessment: Scoping Review and Thematic Analysis’. Journal of Medical Internet Research 26 (10 April 2024): e48694. https://doi.org/10.2196/48694.
  170. Shepherd, A. ‘HTA as a Framework for Task Analysis’. Ergonomics 41, no. 11 (1 November 1998): 1537-1552. https://doi.org/10.1080/001401398186063.
  171. Simoens, Steven. ‘Health Technology Assessment and Economic Evaluation across Jurisdictions’. Value in Health 13, no. 6 (2010): 857-859. https://doi.org/10.1111/j.1524-4733.2010.00756.x.
  172. Sola-Morales, Oriol, Lesley H. Curtis, Julien Heidt, Laura Walsh, Deborah Casso, Susan Oliveria, Patrick Saunders-Hastings, et al. ‘Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions’. Clinical Pharmacology & Therapeutics 114, no. 2 (2023): 325-355. https://doi.org/10.1002/cpt.2914.
  173. Sorenson, Corinna, and Kalipso Chalkidou. ‘Reflections on the Evolution of Health Technology Assessment in Europe’. Health Economics Policy and Law 7, no. 1 (2012): 25-46.
  174. Spiegelhalter, D J, J P Myles, D R Jones, and K R Abrams. ‘Bayesian Methods in Health Technology Assessment: A Review’. Health Technology Assessment (Winchester, England) 4, no. 38 (1 January 2000): 1-130.
  175. Spontoni, Cristiana, and Elinor Pecsteen. ‘New Commission Proposal for a Regulation on Health Technology Assessment.’ Digital Health Legal 5, no. 3 (2018): 4–6.
  176. Stafinski, Tania, Judith Glennie, Andrea Young, and Devidas Menon. ‘HTA Decision-Making for Drugs for Rare Diseases: Comparison of Processes across Countries’. Orphanet Journal of Rare Diseases 17, no. 1 (8 July 2022): 258. https://doi.org/10.1186/s13023-022-02397-4.
  177. Steigenberger, Caroline, Petra Schnell-Inderst, Uwe Siebert, and Verlag W. Kohlhammer. ‘Integrating Patients and Social Aspects into Health Technology Assessment’. In Defining the Value of Medical Interventions: Normative and Empirical Challenges, edited by Jan Schildmann, Charlotte Buch, and Jürgen Zerth. Wellcome Trust–Funded Monographs and Book Chapters. Stuttgart (DE): W. Kohlhammer GmbH, 2021. http://www.ncbi.nlm.nih.gov/books/NBK585096/.
  178. Stuhlinger, Verena. ‘Health Technology Assessment (HTA) and Access Policies Special Issue: Innovative Medicine and Research: Ethical, Legal and Regulatory Issues’. European Journal of Health Law 27, no. 3 (2020): 274-289. https://doi.org/DOI:10.1163/15718093-BJA10006.
  179. Sullivan, Sean D., John Watkins, Brian Sweet, and Scott D. Ramsey. ‘Health Technology Assessment in Health-Care Decisions in the United States’. Value in Health 12, no. s2 (2009): S39-44. https://doi.org/10.1111/j.1524-4733.2009.00557.x.
  180. Tafuri, Giovanni, Inês Lucas, Steve Estevão, Jane Moseley, Anne d’Andon, Hannah Bruehl, Elangovan Gajraj, et al. ‘The Impact of Parallel Regulatory–Health Technology Assessment Scientific Advice on Clinical Development. Assessing the Uptake of Regulatory and Health Technology Assessment Recommendations’. British Journal of Clinical Pharmacology 84, no. 5 (2018): 1013-1019. https://doi.org/10.1111/bcp.13524.
  181. Tafuri, Giovanni, Margherita Pagnini, Jane Moseley, Marco Massari, Frank Petavy, Antje Behring, Arantxa Catalan, et al. ‘How Aligned Are the Perspectives of EU Regulators and HTA Bodies? A Comparative Analysis of Regulatory-HTA Parallel Scientific Advice’. British Journal of Clinical Pharmacology 82, no. 4 (2016): 965-973. https://doi.org/10.1111/bcp.13023.
  182. Tarricone, Rosanna, Helen Banks, Oriana Ciani, Werner Brouwer, Michael F Drummond, Reiner Leidl, Nicolas Martelli, Laura Sampietro-Colom, and Rod S. Taylor. ‘An Accelerated Access Pathway for Innovative High-Risk Medical Devices under the New European Union Medical Devices and Health Technology Assessment Regulations? Analysis and Recommendations’. Expert Review of Medical Devices 20, no. 4 (3 April 2023): 259-271. https://doi.org/10.1080/17434440.2023.2192868.
  183. Tarricone, Rosanna, Aleksandra Torbica, and Michael Drummond. ‘Challenges in the Assessment of Medical Devices: The MedtecHTA Project’. Health Economics 26, no. S1 (2017): 5-12. https://doi.org/10.1002/hec.3469.
  184. Tarricone, Rosanna, Aleksandra Torbica, Michael Drummond, and for the MedtecHTA Project Group. ‘Key Recommendations from the MedtecHTA Project’. Health Economics 26, no. S1 (2017): 145–52. https://doi.org/10.1002/hec.3468.
  185. Thokala, Praveen, and Alejandra Duenas. ‘Multiple Criteria Decision Analysis for Health Technology Assessment’. Value in Health 15, no. 8 (1 December 2012): 1172-1181. https://doi.org/10.1016/j.jval.2012.06.015.
  186. Vale, Luke. ‘Health Technology Assessment and Economic Evaluation: Arguments for a National Approach’. Value in Health 13, no. 6 (2010): 859-861. https://doi.org/10.1111/j.1524-4733.2010.00765.x.
  187. Valerio, L., and W. Ricciardi. ‘The Current Status of Decision-Making Procedures and Quality Assurance in Europe: An Overview Social Responsibility and Health: Scientific Contribution’. Medicine, Health Care and Philosophy 14, no. 4 (2011): 383-396. https://doi.org/10.1007/s11019-011-9333-0.
  188. Varley, Áine, Lesley Tilson, Emer Fogarty, Laura McCullagh, and Michael Barry. ‘The Utility of a Rapid Review Evaluation Process to a National HTA Agency’. PharmacoEconomics 40, no. 2 (1 February 2022): 203-214. https://doi.org/10.1007/s40273-021-01093-8.
  189. Velasco Garrido, Marcial, Ansgar Gerhardus, John-Arne Røttingen, and Reinhard Busse. ‘Developing Health Technology Assessment to Address Health Care System Needs’. Health Policy 94, no. 3 (1 March 2010): 196-202. https://doi.org/10.1016/j.healthpol.2009.10.002.
  190. Vella Bonanno, Patricia, Anna Bucsics, Steven Simoens, Antony P Martin, Wija Oortwijn, Jolanta Gulbinovič, Celia Rothe, et al. ‘Proposal for a Regulation on Health Technology Assessment in Europe – Opinions of Policy Makers, Payers and Academics from the Field of HTA’. Expert Review of Pharmacoeconomics & Outcomes Research 19, no. 3 (4 May 2019): 251-261. https://doi.org/10.1080/14737167.2019.1575730.
  191. Vis, Christiaan, Leah Bührmann, Heleen Riper, and Hans C. Ossebaard. ‘Health Technology Assessment Frameworks for EHealth: A Systematic Review’. International Journal of Technology Assessment in Health Care 36, no. 3 (June 2020): 204-216. https://doi.org/10.1017/S026646232000015X.
  192. Vreman, Rick A., Angela S. de Ruijter, Anna Zawada, Giovanni Tafuri, Violeta Stoyanova-Beninska, Daniel O’Connor, Frauke Naumann-Winter, et al. ‘Assessment of Significant Benefit for Orphan Medicinal Products by European Regulators May Support Subsequent Relative Effectiveness Assessments by Health Technology Assessment Organizations’. Drug Discovery Today 25, no. 7 (1 July 2020): 1223-1231. https://doi.org/10.1016/j.drudis.2020.04.012.
  193. Vukovic, Vladimir, Carlo Favaretti, Walter Ricciardi, and Chiara de Waure. ‘Health Technology Assessment evidence on e-health/m-health technologies: evaluating the transparency and thoroughness’. International Journal of Technology Assessment in Health Care 34, no. 1 (January 2018): 87-96. https://doi.org/10.1017/S0266462317004512.
  194. Wakutsu, Naohiko, Emi Hirose, Naohiro Yonemoto, and Sven Demiya. ‘Assessing Definitions and Incentives Adopted for Innovation for Pharmaceutical Products in Five High-Income Countries: A Systematic Literature Review’. Pharmaceutical Medicine 37, no. 1 (1 January 2023): 53-70. https://doi.org/10.1007/s40290-022-00457-5.
  195. Wang, Ting, Neil McAuslane, Helga Gardarsdottir, Wim G. Goettsch, and Hubert G. M. Leufkens. ‘Building HTA Insights into the Drug Development Plan: Current Approaches to Seeking Early Scientific Advice from HTA Agencies’. Drug Discovery Today 27, no. 1 (1 January 2022): 347-353. https://doi.org/10.1016/j.drudis.2021.09.014.
  196. Weinberg, Matthew. ‘Reimbursement in Europe: Health Technology Assessment and What the Future May Hold Global Corner’. FDLI Update 2008, no. 4 (2008): 43-44.
  197. Wested, Jakob. ‘The New Regulation of Health Technology Assessments Reports’. European Health and Pharmaceutical Law Review (EHPL) 6, no. 3 (2022): 122-126.https://doi.org/DOI: 10.21552/ehpl/2022/3/6.
  198. Wise, Jacqui. ‘European Medicines Agency Is Attacked over Proposal to Allow Technology Assessment Bodies to Sell Advice to Drug Industry’. BMJ: British Medical Journal 349 (2014). https://doi.org/0.1136/bmj.g4674.
  199. Wiyani, Anggie, Lohit Badgujar, Vivek Khurana, and Nicholas Adlard. ‘How Have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review’. Neurology and Therapy 10, no. 2 (1 December 2021): 557-583. https://doi.org/10.1007/s40120-021-00264-1.
  200. Wolters, Sharon, Lisa A de Jong, Christel Jansen, Frank GA Jansman, and Maarten J Postma. ‘Differences in Evidentiary Requirements for Oncology Drug Effectiveness Assessments among Six European Health Technology Assessment Bodies — Can Alignment Be Improved?’ Expert Review of Pharmacoeconomics & Outcomes Research 24, no. 2 (7 February 2024): 251-265. https://doi.org/10.1080/14737167.2023.2263166.
  201. Xhaferri, Zamira. ‘Delegated Rulemaking by the European Commission in Practice’. In Law and Practices of Delegated Rulemaking by the European Commission, 154-273. Brill Nijhoff, 2023. https://doi.org/10.1163/9789004523524_005.
  202. Zelei, Tamás, Mária J. Molnár, Márta Szegedi, and Zoltán Kaló. ‘Systematic Review on the Evaluation Criteria of Orphan Medicines in Central and Eastern European Countries’. Orphanet Journal of Rare Diseases 11, no. 1 (4 June 2016): 72. https://doi.org/10.1186/s13023-016-0455-6.

Central and Eastern European Countries

Németh, Bertalan, Wim Goettsch, Finn Børlum Kristensen, Oresta Piniazhko, Mirjana Huić, Tomáš Tesař, Dragana Atanasijevic, Iga Lipska, and Zoltán Kaló. ‘The Transferability of Health Technology Assessment: The European Perspective with Focus on Central and Eastern European Countries’. Expert Review of Pharmacoeconomics & Outcomes Research 20, no. 4 (3 July 2020): 321-330. https://doi.org/10.1080/14737167.2020.1779061.

Czech Republic

  1. Loblova, Olga. ‘Who’s Afraid of Institutionalizing Health Technology Assessment (HTA): Interests and Policy Positions on HTA in the Czech Republic’. Health Economics Policy and Law 13, no. 2 (2018): 137-161. https://doi.org/10.1017/S174413311700024X.
  2. Németh, Bertalan, Wim Goettsch, Finn Børlum Kristensen, Oresta Piniazhko, Mirjana Huić, Tomáš Tesař, Dragana Atanasijevic, Iga Lipska, and Zoltán Kaló. ‘The Transferability of Health Technology Assessment: The European Perspective with Focus on Central and Eastern European Countries’. Expert Review of Pharmacoeconomics & Outcomes Research 20, no. 4 (3 July 2020): 321-330. https://doi.org/10.1080/14737167.2020.1779061.

 

France

  1. Benamouzig, Daniel. ‘NICE et les interférences pharmaceutiques. La négociation de prix exorbitants’. Revue française des affaires sociales, no. 3 (2018): 181-201. https://doi.org/10.3917/rfas.183.0181.
  2. Dutot, Camille, Grégoire Mercier, Isabelle Borget, Côme de Sauvebeuf, and Nicolas Martelli. ‘Hospital-Based Health Technology Assessment for the Adoption of Innovative Medical Devices within French Hospitals: Opportunities and Challenges for Industry’. International Journal of Technology Assessment in Health Care 33, no. 2 (January 2017): 297-302. https://doi.org/10.1017/S0266462317000368.
  3. Ghabri, Salah, Anne-Isabelle Poullié, Erwan Autin, and Jean-Michel Josselin. ‘Le guide d’analyse d’impact budgétaire de la HAS : un nouvel outil d’aide à la décision’. Santé Publique 29, no. 4 (2017): 585-588. https://doi.org/10.3917/spub.174.0585.
  4. ‘Innovation et qualité : l’ordonnance de la HAS’. Protection Sociale Informations, no. 1130 (18 July 2018).
  5. Jacquet, Laurie Rachet, Léa Toulemon, Véronique Raimond, Albane Degrassat-Théas, Lise Rochaix, and Pascal Paubel. ‘Le prix des médicaments en France : présentation synthétique des évolutions récentes du système français de fixation des prix’. Revue française des affaires sociales, no. 3 (2018): 47-67. https://doi.org/10.3917/rfas.183.0047.
  6.  Kammerer, Mariette. ‘La Haute Autorité de santé annonce de nouveaux outils pour encourager la participation des usagers à ses travaux’. Protection Sociale Informations, no. No 1337 (22 November 2022). 
  7.  Le Pen, Claude. ‘Une (brève) histoire de la Commission de la transparence’. Revue française des affaires sociales, no. 3 (2018): 111-127. https://doi.org/10.3917/rfas.183.0111.
  8. Martelli, N., H. van den Brink, F. Denies, B. Dervaux, A. F. Germe, P. Prognon, and J. Pineau. ‘Évaluation des technologies de santé en milieu hospitalier : quelle organisation pour évaluer et acquérir des dispositifs médicaux innovants ?’ Annales Pharmaceutiques Françaises 72, no. 1 (1 January 2014): 3-14. https://doi.org/10.1016/j.pharma.2013.09.002.
  9. Mills, Mackenzie, and Panos Kanavos. ‘How Do HTA Agencies Perceive Conditional Approval of Medicines? Evidence from England, Scotland, France and Canada’. Health Policy 126, no. 11 (1 November 2022): 1130-1143. https://doi.org/10.1016/j.healthpol.2022.08.005.
  10.  Orvain, Jacques, Bertrand Xerri, and Yves Matillon. ‘Overview of Health Technology Assessment in France’. International Journal of Technology Assessment in Health Care 20, no. 1 (January 2004): 25-34. https://doi.org/10.1017/S0266462304000753.

Germany

  1. Conrads-Frank, Annette, Petra Schnell-Inderst, Silke Neusser, Lára R. Hallsson, Igor Stojkov, Silke Siebert, Felicitas Kühne, Beate Jahn, Uwe Siebert, and Gabi Sroczynski. ‘Decision-Analytic Modeling for Early Health Technology Assessment of Medical Devices – a Scoping Review’. GMS German Medical Science 20 (21 December 2022): Doc11. https://doi.org/10.3205/000313.
  2. Fricke, Frank-Ulrich, and Hans Peter Dauben. ‘Health Technology Assessment: A Perspective from Germany’. Value in Health 12, no. s2 (2009): S20-27. https://doi.org/10.1111/j.1524-4733.2009.00555.x.
  3. Hart, Dieter. ‘Recent Developments in German Health Law’. European Journal of Health Law 13, no. 2 (2006): 101-106.
  4. Orth, Matthias. ‘Are Regulation-Driven Performance Criteria Still Acceptable? – The German Point of View’. Clinical Chemistry and Laboratory Medicine (CCLM) 53, no. 6 (1 May 2015): 893-898. https://doi.org/10.1515/cclm-2014-1144.

Greece

Tsakalogiannis, Christos, Eleftheria Karampli, Kostas Athanasakis, and John Kyriopoulos. ‘The Role of Health Technology Assessment in Pharmaceutical Policy Decision-Making in Greece. Findings from a Qualitative Study’. Journal of Pharmaceutical Health Services Research 10, no. 4 (2019): 439-441. https://doi.org/10.1111/jphs.12319.

Hungary

  1. Csanadi, Marcell, Olga Loblova, Piotr Ozieranski, Andras Harsanyi, Zoltan Kalo, Martin McKee, and Lawrence King. ‘When Health Technology Assessment Is Confidential and Experts Have No Power: The Case of Hungary’. Health Economics Policy and Law 14, no. 2 (2019): 162-181. https://doi:10.1017/S1744133118000051.
  2. Mezei, Fruzsina, Krisztián Horváth, Máté Pálfi, Kornélia Lovas, Ildikó Ádám, and Gergő Túri. ‘International Practices in Health Technology Assessment and Public Financing of Digital Health Technologies: Recommendations for Hungary’. Frontiers in Public Health 11 (2023): 1197949. https://doi.org/10.3389/fpubh.2023.1197949.
  3. Németh, Bertalan, Wim Goettsch, Finn Børlum Kristensen, Oresta Piniazhko, Mirjana Huić, Tomáš Tesař, Dragana Atanasijevic, Iga Lipska, and Zoltán Kaló. ‘The Transferability of Health Technology Assessment: The European Perspective with Focus on Central and Eastern European Countries’. Expert Review of Pharmacoeconomics & Outcomes Research 20, no. 4 (3 July 2020): 321-330. https://doi.org/10.1080/14737167.2020.1779061.

Ireland

  1. Kinchin, Irina, Valerie Walshe, Charles Normand, Joanna Coast, Rachel Elliott, Thilo Kroll, Philip Kinghorn, et al. ‘Expanding Health Technology Assessment towards Broader Value: Ireland as a Case Study’. International Journal of Technology Assessment in Health Care 39, no. 1 (2 May 2023): e26. https://doi.org/10.1017/S0266462323000235.
  2. Smith, Amelia, and Michael Barry. ‘Combining Health Technology Assessment and Health Technology Management to Deliver Cost-Effective Prescribing and Cost Containment - the Irish Experience’. Expert Review of Pharmacoeconomics & Outcomes Research 20, no. 5 (October 2020): 431-436. https://doi.org/10.1080/14737167.2020.1822739.

Italy

  1. Pitini, Erica, Giuseppe Migliara, Valentina Baccolini, Claudia Isonne, Elena Mazzalai, Federica Turatto, Carla Salerno, et al. ‘Managing the Introduction of Genomic Applications into the National Health Service: A Special Challenge for Health Technology Assessment in Italy’. Frontiers in Public Health 10 (2022): 932093. https://doi.org/10.3389/fpubh.2022.932093.

Netherlands

Enzing, Joost J., Saskia Knies, Bert Boer, and Werner B. F. Brouwer. ‘Broadening the Application of Health Technology Assessment in the Netherlands: A Worthwhile Destination but Not an Easy Ride?’ Health Economics Policy and Law 16, no. 4 (2021): 440-456. https://doi.org/10.1017/s1744133120000237.

Poland

  1. Németh, Bertalan, Wim Goettsch, Finn Børlum Kristensen, Oresta Piniazhko, Mirjana Huić, Tomáš Tesař, Dragana Atanasijevic, Iga Lipska, and Zoltán Kaló. ‘The Transferability of Health Technology Assessment: The European Perspective with Focus on Central and Eastern European Countries’. Expert Review of Pharmacoeconomics & Outcomes Research 20, no. 4 (3 July 2020): 321-330. https://doi.org/10.1080/14737167.2020.1779061
  2. Ozieranski, Piotr, Olga Loblova, Natalia Nicholls, Marcell Csanadi, Zoltan Kalo, Martin McKee, and Lawrence King. ‘Transparency in Practice: Evidence from Verification Analyses Issued by the Polish Agency for Health Technology Assessment in 2012-2015’. Health Economics Policy and Law 14, no. 2 (2018): 182-204. https://doi.org/doi:10.1017/S1744133117000342.

Spain

Pinilla-Dominguez, Pilar, and Jaime Pinilla-Dominguez. ‘Deliberative Processes in Health Technology Assessment of Medicines: The Case of Spain’. International Journal of Technology Assessment in Health Care 39, no. 1 (5 July 2023): e50.https://doi.org/10.1017/S0266462323000387.

United Kingdom

  1. Benamouzig, Daniel. ‘NICE et les interférences pharmaceutiques. La négociation de prix exorbitants’. Revue française des affaires sociales, no. 3 (2018): 181-201. https://doi.org/10.3917/rfas.183.0181.
  2. Briscoe, Simon. ‘Web Searching for Systematic Reviews: A Case Study of Reporting Standards in the UK Health Technology Assessment Programme’. BMC Research Notes 8, no. 1 (16 April 2015): 153. https://doi.org/10.1186/s13104-015-1079-y.
  3. Cerri, Karin H., Martin Knapp, and Jose-Luis Fernandez. ‘Decision Making by NICE: Examining the Influences of Evidence, Process and Context’. Health Economics Policy and Law 9, no. 2 (2014): 119-142. https://doi.org/10.1017/1S744133113000030.
  4. Cooper, Christopher, and Sabrina Smith. ‘The International HTA Database Returned Incomplete Search Results for NICE Technology Appraisals: An Exploratory Study and Discussion of the Implications’. Cochrane Evidence Synthesis and Methods 1, no. 10 (2023): e12034. https://doi.org/10.1002/cesm.12034.
  5. Cooper, Nicola, Douglas Coyle, Keith Abrams, Miranda Mugford, and Alexander Sutton. ‘Use of Evidence in Decision Models: An Appraisal of Health Technology Assessments in the UK since 1997’. Journal of Health Services Research & Policy 10, no. 4 (2005): 245-250.
  6. Drummond, Michael, and Corinna Sorenson. ‘Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom’. Value in Health 12, no. s2 (2009): S8-13. https://doi.org/10.1111/j.1524-4733.2009.00552.x
  7. Gallacher, Daniel, Nigel Stallard, Peter Kimani, Elvan Gökalp, and Juergen Branke. ‘Development of a Model to Demonstrate the Impact of National Institute of Health and Care Excellence Cost-Effectiveness Assessment on Health Utility for Targeted Medicines’. Health Economics 31, no. 2 (2022): 417-430. https://doi.org/10.1002/hec.4459.
  8. Mills, Mackenzie, and Panos Kanavos. ‘How Do HTA Agencies Perceive Conditional Approval of Medicines? Evidence from England, Scotland, France and Canada’. Health Policy 126, no. 11 (1 November 2022): 1130-1143. https://doi.org/10.1016/j.healthpol.2022.08.005.
  9. Raftery, James, and John Powell. ‘Health Technology Assessment in the UK’. The Lancet 382, no. 9900 (12 October 2013): 1278-1285. https://doi.org/10.1016/S0140-6736(13)61724-9.
  10. Ridyard, Colin H., and Dyfrig A. Hughes. ‘Methods for the Collection of Resource Use Data within Clinical Trials: A Systematic Review of Studies Funded by the UK Health Technology Assessment Program’. Value in Health 13, no. 8 (2010): 867-872. https://doi.org/10.1111/j.1524-4733.2010.00788.x.
  11. Tolley, Keith. ‘Pharmaceutical Market Access and the Challenges of Health Technology Assessment in the United Kingdom’. Drug Development Research 71, no. 8 (2010): 478-484. https://doi.org/10.1002/ddr.20422.
  12. Tubeuf, Sandy. ‘Évaluation économique des technologies de santé du NICE : un regard expert’. Les Tribunes de la santé 27, no. 2 (2010): 79-90. https://doi.org/10.3917/seve.027.0079.
  13. Walters, Stephen J., Ines Bonacho Dos Anjos Henriques-Cadby, Oscar Bortolami, Laura Flight, Daniel Hind, Richard M. Jacques, Christopher Knox, et al. ‘Recruitment and Retention of Participants in Randomised Controlled Trials: A Review of Trials Funded and Published by the United Kingdom Health Technology Assessment Programme’. BMJ OPEN 7, no. 3 (March 2017): e015276. https://doi.org/10.1136/bmjopen-2016-015276.

Acknowledgements and Copyright

Published: 27/05/2026

Authors:

Luc-Sylvain Gilbert, EuroGCT information officer on Ethical, Legal and Societal Issues

Aurélie Mahalatchimy, EuroGCT WP4 Convenor, UMR 7318 DICE CERIC, Aix-Marseille University, CNRS, Aix-en-Provence, France

Table of contents

Did you find the content on this page useful? If not, you can leave us a message so we can improve Send us your thoughts
-
Your feedback helps us keep EuroGCT online. Please can you take 30 seconds to answer these quick questions?
How would you rate your experience using EuroGCT.org today?
Poor
Great
Is the information on this website understandable?
Not at all understandable
Very understandable
Is the information on this website useful?
Not at all useful
Very useful
Is the website easy to use and navigate?
Not at all easy
Very easy
Why are you interested in gene and cell therapies and research?
CAPTCHA